Saturday, January 15, 2005
cracking cancer drug - (no - not crack!)
Native Americans and medicinal herbs users are once again proven right...!
Ironic is it not - when one knows that science and technological advances contribute so much to the depleting of this ecosystem we are a part of... sometimes it may be done for good causes, but not always.
From time to time, science will give nature a "nudge" - no more... never a full hand!
And now science expects nature to give back... to keep on giving in fact... more than it has already given?!?
We are squeezing the lemon dry, or so it appears...
Details... in the comments section.
FREDERICK, Md. (AP) - Somewhere within a vast, frozen storehouse of tree bark, fungi and marine creatures, a breakthrough cancer drug may be hiding.
Cracking the code begins with crushing the samples kept in the National Cancer Institute's repository on the grounds of Fort Detrick.
Just one in 40,000 natural products yields an effective drug but scientists say the next Taxol - an anti-cancer agent derived from the bark of the Pacific yew tree - could be lurking in one of the repository's 200,000 bar-coded extracts.
"Pharmaceutical companies seem to be really interested in natural products as the source of new drugs, and nature really is the architect of these beautiful new molecules," said Gordon M. Cragg, head of the agency's Natural Products Branch.
Cragg and David J. Newman, who heads the collection program, recently led reporters on a tour of the site. In the repository, bags of vegetable matter, marine mollusks and other organic materials from around the world are stored in 20 double-stacked, walk-in coolers.
The coolers also hold extracts made by grinding, soaking and dissolving such materials. That work is done in a nearby lab run by contractor Science Applications International Corp.
Lab manager Thomas G. McCloud said the extracts, in 120-millilitre glass bottles, contain a wealth of information.
"These are not really bottles; these are library books," he said.
Reading their secrets is a laborious process. Each specimen yields two extracts - one water-based and one in an organic solvent such as oil. Each is tested against multiple kinds of cancer cells including leukemia, melanomas, and cancers of the lung, kidney, colon, central nervous system, ovaries, breast and prostate.
Any extract that shows anti-cancer effects is separated into compounds that are then tested against the same cells in hopes of isolating the active ingredients. Active compounds are tested in laboratory animals, and may then move on to pre-clinical and clinical trials conducted by the NCI or drug companies.
Of the approximately 20,000 extracts tested each year, 98 per cent show no activity against cancer or AIDS.
The costs of creating a marketable drug from a natural product are staggering. The General Accounting Office reports that the National Institutes of Health spent $183 million US over 20 years for research on Taxol, which was approved for sale in 1992. The drug, used mainly against breast and ovarian cancers, is one of the bestselling cancer drugs in U.S. history.
Taxol is one of seven plant-derived anti-cancer drugs that have received Food and Drug Administration approval for commercial production since 1960, when screening of natural products began.
Two of the approved drugs are derived from a tree native to China, Camptotheca acuminata. They are topotecan, manufactured under the brand name Hycamptin and used to treat lung and ovarian cancer; and irinotecan, made under the brand name Camptosar for use against colorectal cancer.
Besides the search for anti-cancer agents, NCI began screening plants for anti-AIDS compounds in 1988. Five chemicals showing significant activity against AIDS have been isolated through that program and three are in pre-clinical development. They are calanolide A and calanolide B, isolated from trees found in Malaysia, and conocurovone, isolated from the saltbush shrub of western Australia.
Screening of marine organisms began in 1975. That program has produced four anti-cancer candidates that are now in pre-clinical or clinical development. Their sources are a large sea slug from the Comoros Islands in the western Indian Ocean, a Caribbean sea squirt, a tiny moss animal called a bryozoan that was collected off the California coast, and a New Zealand sponge.
Newman said marine environments hold huge promise for new medical discoveries.
"The coral reefs are the rain forests of the ocean," he said. "If you take one square metre of a coral reef, you have over 1,000 different species on that square metre. That does not take into account the cryptic organisms which only come out at night and, I might add, does not take into account the world's greatest source of biodiversity, which is, in fact, the marine microbe."
Terrestrial microbial species - essentially fungi - are cultivated at the lab. Several agents isolated from those sources, mainly Streptomyces species, are in pre-clinical or clinical development for the treatment of cancer, the NCI said.